The closed-loop system dynamically self-adjusts DBS therapy to individual brain activity in real time, providing personalized ...
T here is still no cure for Parkinson’s disease, but the U.S. Food and Drug Administration (FDA) approved a new deep brain ...
The U.S. Food and Drug Administration has approved Medtronic's deep brain stimulation system for use in patients with ...
9hon MSN
Medtronic ( MDT 2.27%) and Johnson & Johnson ( JNJ 1.64%) are two very healthy, high-yielding dividend stocks. This makes ...
3don MSN
Medical device manufacturer Medtronic (NYSE: MDT) is a healthcare industry stalwart. The company, based in the U.S. and ...
Medtronic posted a strong profit for Q3 of fiscal year 2025, though shares were down as its cardiac ablation product success ...
The revenue miss came as sales at Medtronic's Medical Surgical division declined 1.9% to $2.07 billion. The company pointed ...
Shares of Medtronic ( MDT -6.63%) were sinking 7.3% as of 11:21 a.m. ET on Tuesday. The decline came after the medical device ...
The FDA approved Medtronic's BrainSense Adaptive DBS and Electrode Identifier for Parkinson's, enhancing therapy ...
Jeff Jonas, portfolio manager at Gabelli Funds, said he’s surprised at the drop in Medtronic’s stock on the heels of its ...
The BrainSense adaptive deep brain stimulation system personalizes therapy by dynamically adjusting stimulation based on real ...
The massive robot-making, pacemaker-inventing medtech company Medtronic is facing a financial snag: the humble stapler.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback